Decreased survival in diabetic patients with pancreatic cancer
As reported in the British Journal of Cancer, patients with diabetes (n=62) are at increased risk of death from pancreatic cancer overall (HR=1.52) and within 3 years of diagnosis (HR=1.45).
Vildegliptin superior to glimepiride when added to metformin
As reported in Metabolism, addition of vildegliptin (50 mg bid) to metformin in T2DM patients inadequately controlled on metformin alone was superior to the addition of glimepiride (2 mg tid) to metformin. Patients on the vildegliptin + metformin regimen lost more weight, had an improved lipid profile, had increased insulin sensitivity, and decreased post-prandial lipemia and insulinemia compared to patients on the glimepiride + metformin regimen.
Parenteral vitamin D improves insulin sensitivity
As reported in Swiss Medical Weekly, supplemental vitamin D3 (300,000 IU im) in patients (n=55) with T2DM of > 10 y duration resulted in a 12.8% decrease in HOMA-IR at 6 months compared to an increase of 10% in patients who received placebo.